Literature DB >> 31685998

Further delineation of neuropsychiatric findings in Tatton-Brown-Rahman syndrome due to disease-causing variants in DNMT3A: seven new patients.

Jair Tenorio1,2, Pablo Alarcón3, Pedro Arias1,2, Irene Dapía1,2, Sixto García-Miñaur1,2, María Palomares Bralo1,2, Jaume Campistol4, Salvador Climent5, Irene Valenzuela6,7, Sergio Ramos1,2, Antonio Martínez Monseny8, Fermina López Grondona6, Javier Botet9, Mercedes Serrano2,4,8, Mario Solís1,2, Fernando Santos-Simarro1,2, Sara Álvarez9, Gisela Teixidó-Tura6, Alberto Fernández Jaén10, Gema Gordo1,2, María Belén Bardón Rivera11, Julián Nevado1,2, Alicia Hernández1,2, Juan C Cigudosa9, Víctor L Ruiz-Pérez2,12, Eduardo F Tizzano7, Pablo Lapunzina13,14.   

Abstract

Tatton-Brown-Rahman (TBRS) syndrome is a recently described overgrowth syndrome caused by loss of function variants in the DNMT3A gene. This gene encodes for a DNA methyltransferase 3 alpha, which is involved in epigenetic regulation, especially during embryonic development. Somatic variants in DNMT3A have been widely studied in different types of tumors, including acute myeloid leukemia, hematopoietic, and lymphoid cancers. Germline gain-of-function variants in this gene have been recently implicated in microcephalic dwarfism. Common clinical features of patients with TBRS include tall stature, macrocephaly, intellectual disability (ID), and a distinctive facial appearance. Differential diagnosis of TBRS comprises Sotos, Weaver, and Malan Syndromes. The majority of these disorders present other clinical features with a high clinical overlap, making necessary a molecular confirmation of the clinical diagnosis. We here describe seven new patients with variants in DNMT3A, four of them with neuropsychiatric disorders, including schizophrenia and psychotic behavior. In addition, one of the patients has developed a brain tumor in adulthood. This patient has also cerebral atrophy, aggressive behavior, ID, and abnormal facial features. Clinical evaluation of this group of patients should include a complete neuropsychiatric assessment together with psychological support in order to detect and manage abnormal behaviors such as aggressiveness, impulsivity, and attention deficit-hyperactivity disorder. TBRS should be suspected in patients with overgrowth, ID, tall stature, and macrocephaly, who also have some neuropsychiatric disorders without any genetic defects in the commonest overgrowth disorders. Molecular confirmation in these patients is mandatory.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31685998      PMCID: PMC7080728          DOI: 10.1038/s41431-019-0485-3

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  42 in total

1.  A case of familial transmission of the newly described DNMT3A-Overgrowth Syndrome.

Authors:  Gabrielle Lemire; Julie Gauthier; Jean-François Soucy; Marie-Ange Delrue
Journal:  Am J Med Genet A       Date:  2017-04-27       Impact factor: 2.802

Review 2.  Risk of tumorigenesis in overgrowth syndromes: a comprehensive review.

Authors:  Pablo Lapunzina
Journal:  Am J Med Genet C Semin Med Genet       Date:  2005-08-15       Impact factor: 3.908

3.  Autosomal dominant cerebellar ataxia deafness and narcolepsy.

Authors:  A Melberg; J Hetta; N Dahl; I Nennesmo; M Bengtsson; R Wibom; C Grant; K H Gustavson; P O Lundberg
Journal:  J Neurol Sci       Date:  1995-12       Impact factor: 3.181

Review 4.  The DNA methyltransferase family: a versatile toolkit for epigenetic regulation.

Authors:  Frank Lyko
Journal:  Nat Rev Genet       Date:  2017-10-16       Impact factor: 53.242

5.  DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development.

Authors:  M Okano; D W Bell; D A Haber; E Li
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

6.  Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy.

Authors:  Juliane Winkelmann; Ling Lin; Barbara Schormair; Birgitte R Kornum; Juliette Faraco; Giuseppe Plazzi; Atle Melberg; Ferdinando Cornelio; Alexander E Urban; Fabio Pizza; Francesca Poli; Fabian Grubert; Thomas Wieland; Elisabeth Graf; Joachim Hallmayer; Tim M Strom; Emmanuel Mignot
Journal:  Hum Mol Genet       Date:  2012-02-09       Impact factor: 6.150

7.  Dnmt3a and Dnmt3b Associate with Enhancers to Regulate Human Epidermal Stem Cell Homeostasis.

Authors:  Lorenzo Rinaldi; Debayan Datta; Judit Serrat; Lluis Morey; Guiomar Solanas; Alexandra Avgustinova; Enrique Blanco; José Ignacio Pons; David Matallanas; Alex Von Kriegsheim; Luciano Di Croce; Salvador Aznar Benitah
Journal:  Cell Stem Cell       Date:  2016-07-28       Impact factor: 24.633

8.  Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss.

Authors:  Christopher J Klein; Maria-Victoria Botuyan; Yanhong Wu; Christopher J Ward; Garth A Nicholson; Simon Hammans; Kaori Hojo; Hiromitch Yamanishi; Adam R Karpf; Douglas C Wallace; Mariella Simon; Cecilie Lander; Lisa A Boardman; Julie M Cunningham; Glenn E Smith; William J Litchy; Benjamin Boes; Elizabeth J Atkinson; Sumit Middha; P James B Dyck; Joseph E Parisi; Georges Mer; David I Smith; Peter J Dyck
Journal:  Nat Genet       Date:  2011-05-01       Impact factor: 38.330

9.  Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability.

Authors:  Katrina Tatton-Brown; Sheila Seal; Elise Ruark; Jenny Harmer; Emma Ramsay; Silvana Del Vecchio Duarte; Anna Zachariou; Sandra Hanks; Eleanor O'Brien; Lise Aksglaede; Diana Baralle; Tabib Dabir; Blanca Gener; David Goudie; Tessa Homfray; Ajith Kumar; Daniela T Pilz; Angelo Selicorni; I Karen Temple; Lionel Van Maldergem; Naomi Yachelevich; Robert van Montfort; Nazneen Rahman
Journal:  Nat Genet       Date:  2014-03-09       Impact factor: 38.330

10.  The Tatton-Brown-Rahman Syndrome: A clinical study of 55 individuals with de novo constitutive DNMT3A variants.

Authors:  Katrina Tatton-Brown; Anna Zachariou; Chey Loveday; Anthony Renwick; Shazia Mahamdallie; Lise Aksglaede; Diana Baralle; Daniela Barge-Schaapveld; Moira Blyth; Mieke Bouma; Jeroen Breckpot; Beau Crabb; Tabib Dabir; Valerie Cormier-Daire; Christine Fauth; Richard Fisher; Blanca Gener; David Goudie; Tessa Homfray; Matthew Hunter; Agnete Jorgensen; Sarina G Kant; Cathy Kirally-Borri; David Koolen; Ajith Kumar; Anatalia Labilloy; Melissa Lees; Carlo Marcelis; Catherine Mercer; Cyril Mignot; Kathryn Miller; Katherine Neas; Ruth Newbury-Ecob; Daniela T Pilz; Renata Posmyk; Carlos Prada; Keri Ramsey; Linda M Randolph; Angelo Selicorni; Deborah Shears; Mohnish Suri; I Karen Temple; Peter Turnpenny; Lionel Val Maldergem; Vinod Varghese; Hermine E Veenstra-Knol; Naomi Yachelevich; Laura Yates; Nazneen Rahman
Journal:  Wellcome Open Res       Date:  2018-04-23
View more
  5 in total

Review 1.  Germline Abnormalities in DNA Methylation and Histone Modification and Associated Cancer Risk.

Authors:  Jenna A Fernandez; Mrinal M Patnaik
Journal:  Curr Hematol Malig Rep       Date:  2022-06-02       Impact factor: 4.213

2.  Aortic root dilatation and dilated cardiomyopathy in an adult with Tatton-Brown-Rahman syndrome.

Authors:  Alana C Cecchi; Amier Haidar; Isabella Marin; Callie S Kwartler; Siddharth K Prakash; Dianna M Milewicz
Journal:  Am J Med Genet A       Date:  2021-10-13       Impact factor: 2.578

Review 3.  MicroRNAs in the Onset of Schizophrenia.

Authors:  Kristen T Thomas; Stanislav S Zakharenko
Journal:  Cells       Date:  2021-10-06       Impact factor: 6.600

Review 4.  Alterations to DNMT3A in Hematologic Malignancies.

Authors:  Kartika Venugopal; Yang Feng; Daniil Shabashvili; Olga A Guryanova
Journal:  Cancer Res       Date:  2020-10-21       Impact factor: 13.312

5.  Functional and epigenetic phenotypes of humans and mice with DNMT3A Overgrowth Syndrome.

Authors:  Amanda M Smith; Taylor A LaValle; Marwan Shinawi; Sai M Ramakrishnan; Haley J Abel; Cheryl A Hill; Nicole M Kirkland; Michael P Rettig; Nichole M Helton; Sharon E Heath; Francesca Ferraro; David Y Chen; Sangeeta Adak; Clay F Semenkovich; Diana L Christian; Jenna R Martin; Harrison W Gabel; Christopher A Miller; Timothy J Ley
Journal:  Nat Commun       Date:  2021-07-27       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.